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I. Abstract 
 Implicit in cellular mechanisms essential for learning and memory, NMDA receptors 
are heterotetrameric members of the family of ionotropic glutamate receptors. Activation of 
the glutamate-specific receptor subunits results in the opening of ion channels, triggering an 
excitatory pathway, which can be moderated by certain endogenous and exogenous 
compounds. Previous research with the endogenous neurosteroids pregnenolone sulfate (PS) 
and 3α-hydroxy-5-β-20-one sulfate (PregS) have indicated that the binding of these 
neurosteroids to NMDA receptors containing the four A-D isoforms of the GluN2 subunit 
affects current flow through them1. Binding of PS to NMDA receptors containing GluN2A or 
GluN2B subunits causes an increased amount of current flow through the channel, whereas 
binding of PS to receptors containing GluN2C and 2D subunits decreases current flow 
through these channels. Binding of PregS to any NMDA receptor also decreases current flow. 
Binding studies from our lab have determined that the neurosteroids PS and PregS bind to the 
amino terminal domain (ATD) of both GluN2B and GluN2D subunits. The ATD segment 
used in these studies consisted of residues 121-292. Binding of both neurosteroids was 
monitored between pH 6.0 and 8.0. Results demonstrated that the binding of PS to GluN2B 
and D ATDs occurred only between pH 6 and 6.5. PregS showed similar pH dependence for 
the GluN2B ATD, although binding was restored at pH 8.  The pH dependence of 
neurosteroid binding suggests the importance of a protonated histidine residue in each 
binding interaction. The GluN2B ATD segment contains one histidine at residue 127, 
whereas the corresponding GluN2D ATD contains 3 histidines at residues 143, 182, and 202. 
Results from preliminary structural and neurosteroid binding studies of His to Ala and Gln 
mutations in the GluN2D ATD are presented. 
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II. Background & Introduction 
 Glutamate is the main excitatory neurotransmitter in the mammalian brain. It is 
involved in many cognitive functions, including learning and memory formation. 
Ionotropic glutamate receptors (iGluRs) are a family of ligand-gated ion channels, 
located in the postsynaptic neural membrane, which open as a response to glycine and the 
neurotransmitter glutamate and are therefore highly controlled1. Glutamate binds to 
specific receptor subunits via an extracellular binding site, inducing a conformational 
change that causes a channel to open in the membrane. When the iGluRs are improperly 
regulated, excess amounts of cations (Na+, Ca 2+, K+) enter the postsynaptic neural cell, 
causing cell death1. This misregulation of iGluRs due to over-activity of the receptors has 
been linked to neurodegenerative diseases such as Huntington’s, Alzheimer’s, and 
Parkinson’s.   
 
 
A. iGluR Family and Structure 
 Included in the iGluR family are alpha-amino-3-hydroxy-5-methyl-4- isoxazole-
propionic acid (AMPA), kainate, delta, and N-methyl-D-aspartate (NMDA) receptors1. 
Each member of the iGluR family is a tetrameric protein, encoded by 18 genes that often 
undergo RNA editing and alternative splicing2. AMPA and kainate receptors are often 
homotetramers, the NMDA receptor is a heterotetramer. Each subunit from the iGluR 
family is modular, as shown in Fig. 1, and contains seven domains. They have an amino 
terminal domain (ATD), which is critical for the interaction between subunits, an extra-
cellular S1S2 neurotransmitter (ligand) binding domain (LBD), three membrane- 
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spanning domains, a re-entrant loop, which forms the pore when the receptor is 
assembled, and a C-terminal tail that is intracellular1. 
 
 
 
 
 
 
 
 
 
Fig 1: Schematic representation of GluR2 domain architecture, composed of extracellular amino terminal 
domain, S1S2 ligand-binding domain (LBD), three transmembrane-spanning regions, a re-entrant loop, and 
an intracellular carboxyl terminal tail. 
 
The NMDA heterotetramer is composed of two GluN1 subunits, which are one of 
eight alternatively spliced versions from a single gene, and two GluN2 subunits (Fig. 2), 
which are one of four versions from separate genes2. The GluN2 subunits are named as 
GluN2A-D. As shown in Fig. 2, GluN1 subunits bind glycine, while GluN2 subunits bind 
the neurotransmitter glutamate. Glutamate binds to the GluN2 subunit as an agonist, and 
glycine binds to the GluN1 subunit as a coagonist. 
Agonist
Linker
C
N
N terminus S1
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Fig 2: The schematic representation of NMDA receptor. NMDA receptor consists of four subunits with the 
ion channel pore in the center. Each subunit is composed of an intracellular C-terminus, four membrane 
domains (M1–4) and extracellular region, where glycine or glutamate binds3. 
 
 The iGluR family is divided according to sequence homology and agonist 
specificity, creating functional heterogeneity that is important for the complex 
functioning of glutamatergic neuro-transmission4. While both receptors are found on the 
extrasynaptic plasma membranes, AMPA receptors are intracellularly associated with the 
endoplasmic reticulum, golgi apparatus, and multi-vesicular bodies4. In contrast, the 
majority of NMDA receptors are expressed on the surface of neurons, concentrated 
around synaptic junctions4.  
 
1. The Amino Terminal Domain 
 While there is much still left to learn about the ATD, recent years have greatly 
elucidated its structure and function. Studies done on NMDA receptor assembly indicate 
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that GluN1 and GluN2 amino terminal domains likely heterodimerize and subsequently 
associate5. This association of two heterodimers is believed to play a key role in 
determining correct NMDA receptor subunit assembly. The ATD was successfully 
proven to control the kinetics of NMDA receptor deactivation. It was also determined that 
the ATD- ligand binding domain linker has an important role in generating this effect, 
and that transplantation of the ATD affected the gating properties of the NMDA receptor 
subtypes concerned.  
 
2. The S1S2 Ligand Binding Domain 
 Although there is currently only one crystal structure for a full-length iGluR, 
crystal structures have been found for the isolated LBDs in 10 subunits of both NMDA 
and AMPA receptors. In AMPA receptors, it has been shown that the LBD is the site of 
action of positive allosteric modulators, some of which cause desensitization while others 
slow excitatory current decay, and recent crystal structures of these GluA2 modulator 
complexes have been solved6. The ligand binding domain consists of two lobes that close 
together upon agonist binding, forming a clamshell-like structure7. In addition to the 
elucidation of these crystal structures, free energy landscape measurements of the GluA2 
LBD in apo and glutamate bound states shows multiple conformations of similar energy 
for the apo protein, which is consistent with the growing idea of a highly dynamic 
molecule8. Simulations have been used for studying the spontaneous opening and closing 
of GluA2, GluK, and NMDA GluN2A subunit LBDs as well, which demonstrate a salt 
bridge network surrounding the clamshell that likely acts as a ligand binding sensor to 
trigger domain closure9.  
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3. Full Length iGluR  
The crystal structure of a full-length rat GluA2 AMPA receptor tetramer has 
recently been determined using X-ray data to 3.6 Å resolution. While this resolution is 
not enough to elucidate specific side chains, it is the first full-length crystal structure of 
an iGluR tetramer to be found10. The crystal structure showed several interesting aspects 
of the GluA2 structure, particularly a cross-over of subunits that form dimer pairs in the 
layers of the amino terminal (ATD) and ligand binding (LBD) domains10 (Fig. 3). It 
appears that the ATD and LBD tetramer assemblies are loosely packed, as evidenced by a 
large cavity observed on the central axis of symmetry at the ATD and LBD interface10.   
 
Fig 3: Domain organization in the GluA2 ion channel crystal structure (PDB 3KG2). (a) The four subunits 
in the tetramer assembly are colored blue, yellow, red and green; the molecular surface representation 
reveals key features of the structure, including its organization in layers, the cavity at the ATD and LBD 
interface, and the large size of the extracellular domains compared to the ion channel. (b) ATD dimer 
formed by chains A and B reveals a large separation of the LBD domains in this subunit pair; linkers that 
connect the layered domains are indicated by black arrows that draw attention to the different 
conformations of the LBD linkers in the A and B subunits. (c) LBD dimer formed by chains A and D 
reveals a large separation of the ATD domains in this subunit pair11. 
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Additional studies on wild type GluA2 receptors revealed that AMPA receptor 
assembly proceeds starting with the formation of dimers, during which the ATD couples 
closely with the trans-membrane segments, whereas the ligand binding domains (LBDs) 
wind up pushed to the side. For AMPA receptors, subunit exchange in the ATD and LBD 
layers appears to be critical to tetramer assembly12. 
 
 
 
B. PS & PREGAS 
 Several endogenous compounds, such as Zn (II), the polyamines spermine and 
spermidine, and the sulfated neurosteroids pregnenolone sulfate (PS) and 3-α -hydroxy-5- 
β-pregnan-20-one sulfate (PregS) have been shown to be involved in the regulation of the 
iGluRs13. PregS is a representative member of neurosteroids that, as shown in Fig. 2, 
inhibit the activity of NMDA receptors, as well as GABAA, AMPA, and kainate 
receptors13. These neurosteroids have been shown to reduce open channel probability and 
time, as well as increase receptor desensitization14. PregS has been demonstrated to be an 
allosteric inhibitor of NMDA receptors, rather than an ion channel blocker or competitive 
inhibitor with glutamate15. Studies have indicated that a PregS inhibitory binding site is 
likely located on the GluN2 subunit, although the exact location is uncertain16. It is the 
elucidation of this neurosteroid binding site that is the focus of this work. 
PS, which is structurally similar to PregS except for one double bond at the 
steroid A/B ring juncture and different orientations of the sulfate group that both 
neurosteroids possess- β orientation in PS, and α orientation in PregS (Fig. 4), inhibits 
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the activity of non-NMDA iGluRs but differentially regulates NMDA receptors17. 
Potentiation with PS has been shown to induce a 200% rise in NMDA receptor response, 
and is believed to be exerted allosterically, via binding to a potentiating site on the 
receptor3. Studies have demonstrated that PS has dual inhibitory and potentiating activity 
at NMDA receptors with GluN2A or B subunits, with potentiation prevailing in 2A or B 
subunits but inhibition prevailing in NMDA receptors with GluN2C or D subunits18. In 
studying PS potentiation it was found that the potentiating effect of the neurosteroid was 
significantly stronger when PS was bound to the receptor prior to the agonist, nearly 
400% compared to 80% potentiation when PS was simultaneously bound with 
glutamate19. This indicates that the PS binding site might interact allosterically with the 
glutamate binding site, although again the exact binding site of both neurosteroids in 
question, PS and PregS, has yet to be elucidated. 
   
 
 
 
 
 
Fig 4: Neurosteroid structures of PS and PregS  
 
One of the primary structural similarities of PS and PregS, shared with all steroids 
that are capable of modulating NMDA receptor function, is the presence of a charged 
group on the C3 of the steroid core, in the case of PS and PregS a sulfate group (Fig 4)20. 
It has also been shown that more planar steroids, of which PS is a characteristic member 
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due to its double bond, typically function as potentiators of NMDA receptor response. 
PregS, characteristic of more ‘bent’ steroids, is also typical in its function as an inhibitory 
neurosteroid21. 
Our lab has shown that both PS and PregS bind to the S1S2 domain of the 
GluN2B subunit of the NMDA receptor, but that they do not bind to the GluN2D S1S2 
domain22. Binding of PS and PregS has been found to occur at the ATD of both GluN2B 
and GluN2D subunits, although the exact binding site is currently unknown.  
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III. RESULTS AND DISCUSSION 
 
 We hypothesized that neurosteroid binding to the GluN2B and GluN2D subunits 
occurred at the amino terminal domain. Previous electrophysiology experiments 
demonstrated that neurosteroids bind to an extracellular region of NMDA receptors, 
although the exact location of this binding was uncertain. Previous experiments from our 
lab demonstrated neurosteroid binding to the S1S2 LBD of AMPA receptors. Further 
fluorescence experiments with NMDA receptors demonstrated that binding of the 
neurosteroids takes place at the GluN2B S1S2 domain, but not the GluN2D S1S2 
domain. This suggests that neurosteroid binding likely occurs at the ATD of both 
subunits.  
 The ATDs of GluN2B and GluN2D subunits are about 400 amino acids long. A 
BLAST homology search was used to determine possible structural domains of these 
ATDs. With homology to a portion of the atrial natriuretic peptide clearance (ANP-C) 
receptor precursor, amino acids 121-292 were chosen for cloning and over-expression.   
To elucidate neurosteroid binding to the GluN2B and 2D ATDs, intrinsic 
fluorescence studies were conducted to observe changes in fluorescence emission upon 
addition of the neurosteroids to each ATD. Intrinsic fluorescence studies measure the 
changes in emission of intrinsic fluors present in proteins, the amino acids tyrosine, 
phenylalanine, and tryptophan. However, tyrosine’s fluorescence emission is easily 
quenched and phenylalanine is known to fluoresce weakly. Therefore, the amino acid 
tryptphan was the amino acid whose emission was measured for fluorescence studies. 
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There are four tryptophans in this short GluN2B ATD, and three tryptophans in the short 
GluN2D ATD. 
 With confirmation of the hypothesis that neurosteroid binding does occur at the 
GluN2B and 2D ATDs came information that neurosteroid binding is pH dependent, with 
binding lost after pH 6.5. It was therefore hypothesized that a specific amino acid residue, 
histidine, played a critical role in neurosteroid binding. Mutations to alter histidine 
residues were conducted and fluorescence studies were done in order to determine if 
neurosteroid binding was altered. 
 
 
A. Cloning, Growth, & Purification of Wild Type Domains 
 GluN2B and GluN2D ATDs were solubly expressed similarly to the S1S2 
domains from GluN2D subunits23. Soluble protein over-expression proved possible after 
transformation into Origami 2(DE3) cells.  
 Circular dichroism (CD) spectroscopy was conducted on wild type (wt) GluN2B 
and GluN2D ATDS, both apo and bound to the neurosteroids PS and PregS to confirm 
the presence of secondary structure (Fig. 5A,B). The crystal structure of the GluN2B 
ATD is known (GluN2D has not yet been crystallized), and has been demonstrated to be 
a mixture of α-helices and β-sheets (Fig. 5C). Far-UV CD spectroscopy confirmed the 
purified GluN2D ATD to be folded and of mixed α-helical/β-sheet character, consistent 
with known structures of the GluN2B ATDs (60% sequence similarity)24 (pdb id 3JPW 
(Fig. 5C)). 
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B. Neurosteroids bind to GluN2B and GluN2D ATDs 
 Intrinsic fluorescence studies demonstrated that both neurosteroids, PS and PregS, 
bind to the GluN2B and GluN2D ATDs (Fig. 6A,B). Binding studies allowed for the 
determination of the dissociation constant, Kd. Calculated Kd values indicate that both PS 
and PregS bind weakly to the GluN2B and 2D ATDs (Fig. 6A,B). PS demonstrated 
similar affinity for GluN2B and 2D ATDs. PregS showed a weaker binding affinity than 
Fig. 5: CD spectra of wt GluN2B 
ATD (5A) and GluN2D ATD (5B) 
Conc. = 1.7 µM, Apo (- - -), with the 
addition of 30 fold molar excess of 
PS (•••) or PREGAS ( ___ ). 
 
(5C) pdb structure of GluN2B ATD- 
GluN2D ATD crystal structure not 
determined. Residues 121-292 in 
blue, His127 in green, residues 4-120 
and 293-404 in white. 
C 
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PS for both ATDs, 2-fold less for the GluN2B ATD, and nearly 6-fold less for the 
GluN2D ATD. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6: Percent fluorescent quenching of PS and PregS to the GluN2B (A) and GluN2D (B) ATD. 
 
 
C. Neurosteroid Binding to Wild Type ATD in pH Dependent Manner 
 In fluorescence binding studies with the endogenous neurosteroids PS and PregS, 
it was found that both neurosteroids bound to the GluN2B and GluN2D ATDs, but only 
at certain pH values (Table 1).  
 
(A) 6.8 µM NMDA GluN2B ATD, pH 6.2 
KD=1.1 
±0.3 mM 
KD=502 
±190 µM 
KD=575 
±278 µM 
 PREGAS  PS 
KD=3.4 
±2.9 mM 
PREGAS PS 
(B) 2.1 µM NMDA GluN2D ATD, pH 6.0 
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pH 6.0 
 
pH 6.5 
 
pH 7.0 
 
pH 7.5 
 
pH 8.0 
 
GluN2B/2D ATD with PS 
 
Y 
 
Y 
 
 
 
 
 
 
 
GluN2B ATD with PREGAS 
 
Y 
 
Y 
 
 
 
 
 
Y 
 
GluN2D ATD with PregS 
 
Y 
 
Y 
 
Y 
 
 
 
Y 
 
Table 1: pH values at which (30-fold molar excess) neurosteroid binding occurs to 6.8 µM 
GluN2B and 2.1 µM 2D ATDs, from intrinsic fluorescence studies. “Y” indicates that binding 
occurs, demonstrated by a change in fluorescence intensity. 
 
 Binding of PS and PregS to the ATD was found to occur at the lower pH values of 
6.0 and 6.5, and was then lost at higher pH values. Binding was restored for PregS at the 
higher pH of 8.0, while PS was still unable to bind to the ATDs at that pH value. The loss 
of binding after pH 6.5 coincides with the ionization of the amino acid histidine, around 
6.10. Histidine remains protonated at pH values lower than its pKa, but at pH values of 7 
or higher, increasingly large proportions of histidine become neutral. It was hypothesized 
that histidine, with its ability to both hydrogen bond and/or ionic bond, played a crucial 
role in neurosteroid binding to the ATD. It was therefore decided to create two mutations 
for each histidine residue present in the amino terminal domain, the first to glutamine, 
which is capable of hydrogen but not ionic bonding, and the second to alanine, capable of 
neither hydrogen nor ionic bonding. By studying whether these two mutants are capable 
of binding to neurosteroids, more can be determined about the exact location of binding, 
as well as the type of binding that neurosteroids rely on to bind to the ATD. Using the 
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crystal structure of the GluN2B ATD (Fig. 5C), the histidine residues for both GluN2B 
and GluN2D ATDs were mapped.  
 The work completed thus far focuses on the GluN2D ATD mutants H143A, 
H182A, H202A, and H202Q. The remaining GluN2D ATD mutants, H143Q and H182Q, 
are currently being purified. In addition, the GluN2B wild-type ATD, as well as the 
H127A and H127Q 2B mutants, are in the process of purification.  
 
D. Mutagenesis, Growth & Purification of GluN2D ATD mutants 
 The ATD of GluN2B has only 1 histidine (amino acid (aa) 127), which will help 
locate the binding pocket. The ATD of GluN2D, however, has 3 histidines, aa 143, 182, 
and 202, which makes identification of the binding pocket more challenging than for the 
NR2B. Mutagenesis of these four histidines was conducted, changing each histidine to 
alanine and glutamine. GluN2B and 2D mutant ATDs were solubly expressed according 
to the protocols established for wild-type amino terminal domains. CD studies were also 
conducted on two GluN2D mutants, histidine 143 to alanine (H143A) and histidine 202 
to glutamine (H202Q) to confirm that the mutation did not result in the loss of secondary 
structure (Fig. 7). 
 
 
 
 
 
 
 
 
 
Fig. 7: CD spectra of H143A (blue) and H202Q (red) GluN2D ATD mutants (apo), 5.2 µM. 
 
(nm) 
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Preliminary results showed that the H143A mutant maintained secondary 
structure similar to that of the wild type GluN2D ATD, although the CD spectrum was 
much weaker for the H202Q mutant than the H143A mutant (Fig. 7). Although only one 
glutamine mutant was investigated, it seems that changing the histidine at 202 to 
glutamine causes a significant degree of unfolding. This indicates that it is possible aa 
202 is crucial for proper folding. Work is currently underway to measure CD spectra for 
all mutants and compare to the wild type protein under the same conditions. 
 
 
E. Fluorescence Studies of GluN2D ATD WT and His Mutants 
 Upon determining that wild type and mutant ATDs had secondary structure, 
intrinsic fluorescence spectroscopy was conducted to determine if there was neurosteroid 
binding to each ATD at five pH values- 6.0, 6.5, 7.0, 7.5, and 8.0 (Table 2, 3). For the 
wild type protein there was not enough to conduct fluorescence at all pH values, so there 
is no fluorescence data for wt at pH 7.0. This will be performed in the future. 
Fluorescence of the wild type GluN2D ATD when bound to PS (Table 2) and PregS 
(Table 3) demonstrated higher quenching of both neurosteroids at the lower pH values of 
6.0 and 6.5, indicating greater binding.  
Intrinsic fluorescence spectroscopy was conducted on four mutant GluN2D 
ATDs- H143A, H182A, H202A, and H202Q at all five pH values. Upon binding of PS to 
the three alanine mutations, there appears to be no significant deviation from the wild 
type binding at the corresponding pH values (Table 2). Thus, although the histidine was 
mutated, and therefore the ability of the ATD at that particular residue to hydrogen bond 
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and/or ionic bond was eliminated, neurosteroid binding can still occur. This indicates that 
either the histidine residues are not important for neurosteroid binding, individually or at 
all, or perhaps that there are other residues nearby with similar pKas (such as glutamate 
or cysteine in unique environments) that are affecting the ability of the neurosteroids to 
bind. The H202Q mutant shows significantly lower ability to bind to PS at all pH values 
(Table 2), however these results are complicated by the CD data (Fig. 7), indicating 
significant unfolding of the mutant.  
 
Table 2: Intrinsic fluorescence quenching of GluN2D ATDs (5.2 µM) in presence of 30 molar 
excess PS. Percent quenching is measured as (Fapo - Fneurosteroid / Fapo) x 100 with error included. 
NQ indicates no quenching. 
 
 
PregS, upon binding to the wild type and mutant ATDs, displayed similar 
tendencies to PS. All three alanine mutants showed a lack of pH dependence, while the 
H202Q mutant bound even more poorly to PregS than to PS (Table 3). It is currently 
hypothesized that this decreased binding occurs because of the weaker secondary 
structure of the H202Q mutant.  
pH 
 
GluN2D WT 
 
H143A 
 
H182A 
 
H202A 
 
H202Q 
 
6.0 
 
24.7 ± 3.9 
 
21.5 ± 2.32 
 
16.3 ± 2.72 
 
28 ± 7.28 
 
6.7 ± 2.28 
 
6.5 
 
20.2 ± 2.9 
 
9.9 ± 5.13 
 
13.6 ± 2.33 
 
18.7 ± 2.22 
 
3.7 ± 2.84 
 
7.0 
 
No studies 
 
8.9 ± 6.39 
 
15.7 ± 0.95 
 
19.2 ± 5.18 
 
8.4 ± 2.8 
 
7.5 
 
6.8 ± 3.12 
 
NQ 
 
15.6 ± 1.43 
 
17.8 ± 0.87 
 
NQ 
 
8.0 
 
13.1 ± 2.5 
 
15.4 ± 5.4 
 
13.6 ± 1.6 
 
18.3 ± 4.61 
 
7.6 ± 3.6 
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Table 3: Intrinsic fluorescence quenching of GluN2D ATDs (5.2 µM) in presence of 30 molar 
excess PregS. Percent quenching is measured as (Fapo - Fneurosteroid / Fapo) x 100 with error included. 
NQ indicates no quenching. 
 
 
 
F. CONCLUSIONS 
 
 After confirming that both neurosteroids bind to the GluN2B and GluN2D ATDs 
in a pH dependent manner, it was hypothesized that histidine’s ability to hydrogen bond 
or ionic bond is crucial to the binding of these neurosteroids. Based on preliminary 
results, it appears that the binding of these neurosteroids is more complicated than 
previously thought. It is possible that a glutamate or cysteine, which have pKas similar to 
histidine in unique environments, could also affect neurosteroid binding. Understanding 
the possible role of these histidines will allow for further elucidation of the neurosteroid 
binding pocket in the ATD. Knowledge of this binding pocket would allow for 
differentiation between potentiation and deactivation of the channel upon binding of the 
neurosteroid to the ATD, which in turn could lead to possible therapeutic targets. 
 
pH 
 
GLuN2D WT 
 
H143A 
 
H182A 
 
H202A 
 
H202Q 
 
6.0 
 
29.1 ± 5.57 
 
17.4 ± 3.55 
 
17.1 ± 4.28 
 
26.6 ± 5.11 
 
NQ 
 
6.5 
 
19.3 ± 2.02 
 
18.7 ± 4.13 
 
10.7 ± 2.9 
 
21.9 ± 2.12 
 
NQ 
 
7.0 
 
No studies 
 
13.0 ± 6.46 
 
14.6 ± 2.77 
 
21.6 ± 3.75 
 
4.9 ± 2.4 
 
7.5 
 
6.9 ± 3.17 
 
NQ 
 
10.4 ± 2.49 
 
12.6 ± 2.26 
 
NQ 
 
8.0 
 
12.7 ± 3.17 
 
NQ 
 
11.5 ± 2.62 
 
15 ± 2.67 
 
NQ 
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IV. EXPERIMENTAL METHODS 
 
A. Cloning 
 The ATDs for the NMDA GluN2B, GluN2D, and AMPA GluA2 subunits (amino 
acids 121-292) were amplified using PCR (rat GluA2 cDNA from Mark Mayer).  After 
restriction digestion (NcoI/XhoI for GluA2 and GluN2D and NcoI/BamHI for GluN2B), 
these inserts were ligated into similarly cut plasmid pET-GQ, (from Eric Gouaux), and 
transformed into Origami 2(DE3) cells (Novagen).  Colonies were screened by PCR and 
then sequenced. 
 
B. Mutagenesis 
Site-directed mutagenesis was conducted using a QuikChange XL kit 
(Stratagene), with primers designed according to Table 4. PCR reactions were set up 
according to Table 5 and run at 95 °C for 2 min, followed by 18 cycles of 95 °C for 1 
min, 68 °C for 50 sec, and 68 °C for 15 min, and ending with one cycle of 68 °C for 7 
min. 1 µl Dpn1 restriction enzyme was then added to each PCR reaction, spun for 1 min, 
and incubated at 37 °C for 60 min. 4 µl Dpn1-treated DNA were then transformed into 
XL-10 ultracompetent cells (Stratagene). XL-10 plasmid DNA was transformed into 
DH5-α competent cells, and next transformed into Origami 2 cells. They were then 
sequenced. 
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GluN2B H127A 5’-CCCATCCTGGGCATCGCTGGGGGCTCATCTAT-3’ 
GluN2B H127Q 5’-CCCATCCTGGGCATCCAAGGGGGCTCA-3’ 
GluN2D H143A 5’-GCGGCGCCGCCGGCCACGGCTACGAT-3’ 
GluN2D H143Q 5’-GCCGCCTTGCACGGCTACGA-3’ 
GluN2D H182A 5’-CAAGAAGGCCCGAGCGCCTGGGCACGC-3’ 
GluN2D H182Q 5’-AAGGCCCGTTGGCCTGGGGCACGC-3’ 
GluN2D H202A 5’-CAGCGCTCCTCGAGCCTCCCAGCCCACC-3’ 
GluN2D H202Q 5’-GCTGGGAGCAACGAGGAGC-3’ 
Table 4: Primer sequences 
 
Mutant: H202Q, H127Q  
(Standard) 
H143A, H143Q, 
H182A, H182Q, 
H202A  
H127A 
Buffer 5 µl 5 µl 2.5 µl 
dsDNA template 10 ng 60 ng 10 ng 
Primer 125 ng  125 ng 31.25 ng  
dNTP 1 µl 1 µl 1 µl 
Quiksolution 3 µl 5 µl none 
Table 5: PCR reaction conditions for specific mutants 
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C. Protein over-expression and purification 
 An overnight of GluN2B or GluN2D ATD in Origami 2(DE3) was used to seed 
1.5 L LB-kan (37 °C), with growth continued until an OD600 of 0.8 was reached. The 
temperature was then lowered to 20 °C for 30 min followed by induction with 1 mM 
IPTG. Growth was continued for 16-18 h at 20 °C, after which time the cells were 
centrifuged for 10 min at 4 °C and 4,000 rpm. The cell pellets were resuspended in 50 
mL buffer A (50 mM Tris, pH 8) containing 5 mM MgSO4, 0.5 mM PMSF, 0.3 mM 
deoxycholic acid, and 16 µM lysozyme, and lysed by sonication. Lysed cells were 
centrifuged at 12,500 rpm for 30 min at 4 °C, and the supernatant loaded onto a nickel 
affinity column (~20 mL, Novagen) and rotated overnight at 4 °C. The column was 
rinsed with 30 mL of 50, 100, 250, and 500 mM, and 1M imidazole in buffer A. Further 
purification for the GluN2B or GluN2D ATD included anion exchange chromatography 
(AEC, GE Q sepharose) at both pH 7.0 and 8.0 (buffer A) followed by size exclusion 
chromatography (SEC, Superdex 75 10/300) at pH 6.0. The purity of each was 
determined by SDS-PAGE. 
 
D. Fluorescence  
Intrinsic fluorescence spectroscopy was performed on a Cary Eclipse fluorometer 
at 25 °C. All emission scans were acquired from 295-380 nm upon excitation at 280 nm. 
Final protein concentrations are as specified in figures (GluN2D ATDs in buffer A). The 
neurosteroids (Steraloids) were solubilized in methanol to 15 mM. A 30:1 molar ratio of 
neurosteroids was added to each iGluR domain. For all fluorescence experiments: (i) 
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before data acquisition, samples were incubated for thirty seconds in the sample holder; 
(ii) to account for any effects methanol had on fluorescence intensity, protein spectra with 
methanol were collected, allowing for direct comparison; (iii) each data set consisted of 
three independent spectra of identically prepared samples. For the GluN2B and 2D wild 
type studies, Kd values were determined by experiments with varying neurosteroid 
concentration from 25-175 molar excess. A double reciprocal plot [1/ΔF = 1/((F∞-
Fo).Kd[L])  + 1/(F∞-Fo)],  was used to determine Kd25. 
 
E. Circular Dichroism Spectroscopy 
CD was performed using a JASCO spectrophotometer. 5.2 µM apo protein was 
added for the GluN2D mutant studies. 1.7 µM GluN2B ATD was used for the wild-type 
CD, with the addition of 30-fold molar excess of PS and PregS. The GluN2D ATD for 
the wild-type CD studies was 1.8 µM, again with 30-fold molar excess of PS and PregS. 
Data was collected from 205-250 nm, 5 times using binomial smoothing (Fig. 5A,B) and 
15 times using means-movement smoothing ( Fig. 7). The spectrophotometer operated at 
room temperature.  
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V. FUTURE WORK 
 The most pressing work to be completed is the growth, purification, and 
successful completion of ligand binding studies as well as CD studies on the remaining 
GluN2D mutants (H182Q and H143Q) as well as GluN2B mutants (H127A and H127Q) 
and the GluN2B wild type ATD. In addition to this, CD thermal denaturation studies will 
be conducted to determine the relative stability of each mutant’s structure as compared to 
the wild type ATD. KD studies are also planned, in order to elucidate the binding affinity 
of neurosteroids for the mutant and wild type ATDs. Upon the completion of these 
studies, double and triple mutants will also be explored, to elucidate if more than one 
histidine residue at a time is important for neurosteroid binding, or if glutamate or 
cysteine play a role. 
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